Online inquiry

IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4514MR)

This product GTTS-WQ4514MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CXCL10 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001565.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3627
UniProt ID P02778
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4514MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13202MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ12289MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ3477MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ7560MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GC33
GTTS-WQ4218MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB029
GTTS-WQ6578MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA DC-1630423
GTTS-WQ8741MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ12416MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NI-0401
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW